Cas­sa­va ends work on Alzheimer's drug; Alu­mis gets $40M up­front from Kak­en

Plus, news about Rel­ma­da Ther­a­peu­tics and Mur­al On­col­o­gy:

Cas­sa­va Sci­ences fi­nal­ly stops work on Alzheimer’s drug: Af­ter a Phase 3 study of simu­fil­am failed in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER